OraPro™: Thermostable, Oral Vaccination Without Needles
The OraPro™ platform uses a novel formulation to protect vaccine vectors (like non-replicating adenoviruses) allowing them to withstand temperatures up to 50°C and survive transit through the stomach. Delivered via an oral capsule, the vaccine is released in the lower small intestine, targeting mucosal cells to initiate an immune response.
Key advantages include:
Needle-Free Delivery: Improves patient acceptance and allows for potential self-administration.
Thermostability: Eliminates costly cold chain requirements for storage and distribution, crucial for global access.
Mucosal & Systemic Immunity: Induces IgA at the site of infection entry, plus systemic IgG and T-cell responses for comprehensive protection.
Reduced Administration Costs: No need for healthcare professionals for administration.
Platform Versatility: Can potentially be used repeatedly for different pathogens or boosters.
Visual: Icons representing benefits (Needle-free, Thermometer/Stable, Shield/Immunity, Cost saving).
